Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-800-3636
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$11.18 million
Profitability
Miscellaneous
Employees230
OptionableOptionable
Achaogen (NASDAQ:AKAO) Frequently Asked Questions
What is Achaogen's stock symbol?
Achaogen trades on the NASDAQ under the ticker symbol "AKAO."
How were Achaogen's earnings last quarter?
Achaogen Inc (NASDAQ:AKAO) posted its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.88) EPS for the quarter, topping the Zacks' consensus estimate of ($0.96) by $0.08. The biopharmaceutical company earned $2 million during the quarter, compared to analyst estimates of $3.80 million. Achaogen had a negative return on equity of 214.74% and a negative net margin of 2,045.86%. View Achaogen's Earnings History.
When is Achaogen's next earnings date?
What price target have analysts set for AKAO?
11 Wall Street analysts have issued 12-month price targets for Achaogen's shares. Their forecasts range from $3.00 to $22.00. On average, they expect Achaogen's stock price to reach $10.8571 in the next twelve months. This suggests a possible upside of 741.6% from the stock's current price. View Analyst Price Targets for Achaogen.
What is the consensus analysts' recommendation for Achaogen?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achaogen in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achaogen.
What are Wall Street analysts saying about Achaogen stock?
Here are some recent quotes from research analysts about Achaogen stock:
- 1. HC Wainwright analysts commented, "916-3963, POS Risk-adj value Full value Rating ZEMDRI – U.S. 100% $1.92 $1.92 Shares outstanding 46,120 2018 ZEMDRI – EU 35% $0.64 $1.83 Current share price $2.25 Discount rate 18.0% C-Scape – U.S." (11/12/2018)
- 2. Mizuho analysts commented, "We currently project a cash runway into mid-2019. In our valuation, we assume a $200 mil capital raise at $3.50/share in 1Q19 and we also increased our discount rate from 10% to 17% to reflect significantly increased risks. Our PT goes to $8." (11/6/2018)
- 3. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (10/17/2018)
Has Achaogen been receiving favorable news coverage?
Media coverage about AKAO stock has trended very positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Achaogen earned a news sentiment score of 3.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are some of Achaogen's key competitors?
Some companies that are related to Achaogen include Aldeyra Therapeutics (ALDX), Seres Therapeutics (MCRB), Dova Pharmaceuticals (DOVA), Magenta Therapeutics (MGTA), TAIWAN LIPOSOME/S (TLC), Syros Pharmaceuticals (SYRS), Strongbridge Biopharma (SBBP), MannKind (MNKD), CELYAD SA/ADR (CYAD), Avid Bioservices (CDMO), Affimed (AFMD), XBiotech (XBIT), Paratek Pharmaceuticals (PRTK), Aratana Therapeutics (PETX) and Kamada (KMDA).
Who are Achaogen's key executives?
Achaogen's management team includes the folowing people:
- Mr. Blake Wise, CEO & Director (Age 48)
- Mr. Gary Loeb, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 49)
- Ms. Zeryn Sarpangal, CFO & Principal Accounting Officer (Age 39)
- Ms. Elizabeth Bhatt, Chief Bus. Officer & COO (Age 50)
- Ms. Jeannie Lloyds, VP of Sales
Who are Achaogen's major shareholders?
Achaogen's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include First Midwest Bank Trust Division (0.12%). Company insiders that own Achaogen stock include Blake Wise, Gary Loeb, Ian Friedland, Janet Dorling, Kenneth J Hillan, Robert W Duggan, Tobin Schilke and Zeryn Sarpangal. View Institutional Ownership Trends for Achaogen.
Which institutional investors are buying Achaogen stock?
How do I buy shares of Achaogen?
Shares of AKAO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achaogen's stock price today?
One share of AKAO stock can currently be purchased for approximately $1.29.
How big of a company is Achaogen?
Achaogen has a market capitalization of $59.49 million and generates $11.18 million in revenue each year. The biopharmaceutical company earns $-125,610,000.00 in net income (profit) each year or ($3.17) on an earnings per share basis. Achaogen employs 230 workers across the globe.
What is Achaogen's official website?
How can I contact Achaogen?
Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-800-3636 or via email at [email protected]
MarketBeat Community Rating for Achaogen (NASDAQ AKAO)
MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe AKAO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKAO will underperform the S&P 500 over the long term. You may vote once every thirty days.
